Japanese Population Prostate Cancer and Benign Prostatic Hyperplasia in a Gene Polymorphism with Vitamin D Receptor Association of Updated Version

Recent studies have suggested that vitamin D is an important determinant of prostate cancer risk and inherited polymorphisms in the 3*untranslated region (3*UTR) of the vitamin D receptor (VDR) gene are associated with the risk and progression of prostate cancer. This study was conducted to explore the association of VDR gene polymorphisms with prostate cancer risk in Japanese men who are considered to be much less influenced by environmental risk factors for prostate cancer. We studied 222 prostate cancer patients, 209 benign prostatic hyperplasia (BPH) patients, 128 male controls who were over 60 years old and without any evidence of prostate cancer or BPH, and 198 female controls. A PCRRFLP method was used to determine threeVDR gene polymorphisms in the 3*UTR characterized by restriction enzymesBsmI, ApaI and TaqI. In the BsmI polymorphism, heterozygosity or homozygosity for the absence of the BsmI restriction site was associated with one-third the risk of prostate cancer (P< 0.0001; odds ratio, 3.31; 95% confidence interval, 2.05–5.32) and with one-half the risk of BPH ( P < 0.005; odds ratio, 2.07; 95% confidence interval, 1.33–3.22) compared with the male controls. The TaqI and ApaI polymorphisms did not show any significant association with either prostate cancer or BPH. The results indicate that theBsmI polymorphism in the VDR gene plays a significant role in protection against prostate cancer and BPH. Because of the racial difference in the strength of the linkage disequilibrium between the three polymorphisms, additional studies are required to apply the present results to other racial-ethnic groups.

[1]  K. Miyazono,et al.  Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. , 1999, Science.

[2]  T. Stamey,et al.  Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) , 1998, The Journal of urology.

[3]  D. Hunter,et al.  Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  K. Burnstein,et al.  Antiproliferative Effect of 1α,25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation. , 1998, Endocrinology.

[5]  G. Hitman,et al.  Allelic variation in the vitamin D receptor influences susceptibility to IDDM in Indian Asians , 1997, Diabetologia.

[6]  D. Morris,et al.  The in vitro effect of vitamin D3 analogue EB-1089 on a human prostate cancer cell line (PC-3). , 1997, British journal of urology.

[7]  A. Hofman,et al.  Vitamin D receptor genotype is associated with radiographic osteoarthritis at the knee. , 1997, The Journal of clinical investigation.

[8]  D. Kiel,et al.  The BsmI Vitamin D Receptor Restriction Fragment Length Polymorphism (bb) Influences the Effect of Calcium Intake on Bone Mineral Density , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  N. Weigel,et al.  1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. , 1997, Endocrinology.

[10]  J. Rastad,et al.  Vitamin D receptor alleles b, a, and T: risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia or MEN 1. , 1997, Biochemical and biophysical research communications.

[11]  G. Coetzee,et al.  Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[12]  G. Coetzee,et al.  Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. , 1997, Journal of the National Cancer Institute.

[13]  M. Becich,et al.  The role of vitamin D in normal prostate growth and differentiation. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[14]  J. Mohler,et al.  Association of prostate cancer with vitamin D receptor gene polymorphism. , 1996, Cancer research.

[15]  J. Eisman,et al.  Vitamin D receptor alleles, bone mineral density and turnover in premenopausal Japanese women , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[16]  H. Guess,et al.  Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. , 1995, The Journal of urology.

[17]  T. Beaty,et al.  Genetic susceptibility of benign prostatic hyperplasia. , 1994, The Journal of urology.

[18]  G. Swanson,et al.  Descriptive epidemiology of prostate cancer in metropolitan detroit , 1994, Cancer.

[19]  T. Stamey,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.

[20]  J. Eisman,et al.  Prediction of bone density from vitamin D receptor alleles , 1994, Nature.

[21]  H. Akaza,et al.  Comparison of various assay systems for prostate-specific antigen standardization. , 1992, Japanese journal of clinical oncology.

[22]  J. Eisman,et al.  Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Lucia,et al.  The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. , 1992, Cancer research.

[24]  J. Shine,et al.  Cloning and expression of full-length cDNA encoding human vitamin D receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Haussler,et al.  Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. , 1987, Science.

[26]  Tetsuro Kato,et al.  [Histological study on hyperplasia of the prostate with special reference to histogenesis of nodule]. , 1967, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[27]  Ames,et al.  Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. , 1997, The New England journal of medicine.

[28]  N. Weigel,et al.  1 , 25-Dihydroxyvitamin D 3 and 9-cis-Retinoic Acid Act Synergistically to Inhibit the Growth of LNCaP Prostate Cells and Cause Accumulation of Cells in G 1 * , 1997 .

[29]  O. Yoshida,et al.  The geography of prostate cancer and its treatment in Japan. , 1995, Cancer surveys.

[30]  D. Peehl,et al.  Actions Of Vitamin D, Analogs on Human Prostate Cancer Cell Lines: Comparison with , 1995 .

[31]  H A Guess,et al.  Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia , 1990, The Prostate.

[32]  B. Hulka,et al.  Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). , 1990, Anticancer research.